Sugi Predict

Sugi Predict / Compounds / SCHEMBL878375

SCHEMBL878375

SCHEMBL878375

O=[C]c1ccccc1COC(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.58
▸ TDP1 Q9NUW8 3/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ SLC6A2 P23975 1/20 0.56
▸ SLC6A3 Q01959 1/20 0.56
▸ RAB9A P51151 3/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ LMNA P02545 3/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ SENP8 Q96LD8 1/20 0.47
▸ SENP7 Q9BQF6 1/20 0.47
▸ SENP6 Q9GZR1 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ TSHR P16473 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ MAPT P10636 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27594582 0.85 NPC1 (0.64) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL5085480 0.84 PPARG (0.71) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL442437 0.79 ALDH1A1 (0.52) TDP1KMT2ARAB9ANPC1LMNA
SCHEMBL4577944 0.79 PPARG (0.65) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL336833 0.77 PPARG (0.63) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL6243415 0.77 PPARG (0.63) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL1268572 0.77 ALDH1A1 (0.37) PPARGTDP1KMT2ARAB9ANPC1
SCHEMBL4445832 0.76 PPARG (0.61) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL471706 0.76 PPARG (0.61) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL5421974 0.76 L3MBTL1 (0.72) PPARGTDP1KMT2ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2177522-B1 NOVEL CARBAPENEM DERIVATIVES XUANZHU PHARMA CO LTD (CN) 2013-09-04 — — EP claimed
US-7579373-B2 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum VIRGINIA COMMONWEALTH UNIVERSITY (US) 2009-08-25 — — US claimed
EP-1427739-A4 TARGETED BISPLATINUM POLYAMINES AS PRO-DRUGS: SELECTIVE RELEASE OF PLATINUM UNIV VIRGINIA COMMONWEALTH (US) 2008-02-13 — — EP claimed
EP-1427739-A1 TARGETED BISPLATINUM POLYAMINES AS PRO-DRUGS: SELECTIVE RELEASE OF PLATINUM VIRGINIA COMMONWEALTH UNIVERSITY (US) 2004-06-16 — — EP claimed
US-20030114433-A1 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum VIRGINIA COMMONWEALTH UNIVERSITY 2003-06-19 — — US claimed
US-6541626-B2 Protecting/blocking the exocyclic amino function of purine nucleosides without effecting hydroxyl groups of sugar moieties via forming activated ester ISIS PHARMACEUTICALS, INC. 2003-04-01 — — US claimed
WO-2003018594-A1 TARGETED BISPLATINUM POLYAMINES AS PRO-DRUGS: SELECTIVE RELEASE OF PLATINUM VIRGINIA COMMONWEALTH UNIVERSITY (US) 2003-03-06 — — WO claimed
US-20030022862-A1 Process for selective N-acylation of purine nucleosides ALLAHABAD, UNIVERSITY OF (IN) 2003-01-30 — — US claimed
WO-2002083702-A1 PROCESS FOR SELECTIVE N-ACYLATION OF PURINE NUCLEOSIDES ISIS PHARMACEUTICALS, INC. (US) 2002-10-24 — — WO claimed
US-5837873-A PROTECTED OXYDIAMINES ABBOTT LABORATORIES (US) 1998-11-17 — — US claimed
US-11999757-B2 Synthesis of boronate ester derivatives and uses thereof MELINTA SUBSIDIARY CORP. (US) 2024-06-04 — — US disclosed
US-11975110-B2 Cationic polymers TRANSLATE BIO, INC. (US) 2024-05-07 — — US disclosed
CN-117986153-A Ionizable cationic lipid compound, and preparation method and application thereof 晟迪生物医药(苏州)有限公司 2024-05-07 — — CN disclosed
EP-4356736-A2 SYNTHESIS OF BORONATE SALTS Melinta Therapeutics, Inc. (US) 2024-04-24 — — EP disclosed
EP-3604316-B1 SYNTHESIS OF BORONATE SALTS MELINTA THERAPEUTICS INC (US) 2023-12-06 — — EP disclosed
EP-0759917-A1 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES GILEAD SCIENCES, INC. (US) 1997-03-05 — — EP disclosed
WO-1996026933-A9 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES — 1996-11-28 — — WO disclosed
WO-1996033200-A1 NOVEL COMPOUNDS AND METHODS FOR THERAPY ÚSTAV ORGANICKÉ CHEMIE A BIOCHEMIE AKADEMIE VED C^¿ESKÉ REPUBLIKY (CZ) 1996-10-24 — — WO disclosed
WO-1996023801-A2 NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME GILEAD SCIENCES, INC. (US) 1996-08-08 — — WO disclosed
US-4508723-A 6-Azaoligocycloalkylmethyleneaminopenam compounds CIBA GEIGY CORPORATION (US) 1985-04-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999757-B2 Synthesis of boronate ester derivatives and uses thereof ADH5, ADH1A, ADH7 PPARG 2580/4885TDP1 1727/4885KMT2A 3000/4885
US-20030022862-A1 Process for selective N-acylation of purine nucleosides PNP, NUDT1, ADAR PPARG 3495/4885TDP1 648/4885KMT2A 2513/4885
US-11975110-B2 Cationic polymers NSUN3, RNMT, POLRMT PPARG 3575/4885TDP1 397/4885KMT2A 2084/4885
US-20030114433-A1 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum SRM, SMS, PARG PPARG 4082/4885TDP1 1009/4885KMT2A 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.